CA2471206A1 - Individualized anti-cancer antibodies - Google Patents

Individualized anti-cancer antibodies Download PDF

Info

Publication number
CA2471206A1
CA2471206A1 CA002471206A CA2471206A CA2471206A1 CA 2471206 A1 CA2471206 A1 CA 2471206A1 CA 002471206 A CA002471206 A CA 002471206A CA 2471206 A CA2471206 A CA 2471206A CA 2471206 A1 CA2471206 A1 CA 2471206A1
Authority
CA
Canada
Prior art keywords
antibodies
fragments
treating
cancerous
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002471206A
Other languages
English (en)
French (fr)
Inventor
David S. F. Young
Miyoko Takahashi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2471206A1 publication Critical patent/CA2471206A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA002471206A 2001-12-21 2001-12-21 Individualized anti-cancer antibodies Abandoned CA2471206A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CA2001/001838 WO2003055515A1 (en) 2001-12-21 2001-12-21 Individualized anti-cancer antibodies

Publications (1)

Publication Number Publication Date
CA2471206A1 true CA2471206A1 (en) 2003-07-10

Family

ID=4143189

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002471206A Abandoned CA2471206A1 (en) 2001-12-21 2001-12-21 Individualized anti-cancer antibodies

Country Status (5)

Country Link
EP (1) EP1455819A1 (ja)
JP (1) JP2005518393A (ja)
AU (1) AU2002226211A1 (ja)
CA (1) CA2471206A1 (ja)
WO (1) WO2003055515A1 (ja)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8048416B2 (en) 1999-10-08 2011-11-01 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US20050100542A1 (en) * 1999-10-08 2005-05-12 Young David S. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7947496B2 (en) 1999-10-08 2011-05-24 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US20040001789A1 (en) * 1999-10-08 2004-01-01 Young David S. F. Cytotoxicity mediation of cells evidencing surface expression of gp96 or precursors thereof
US7252821B2 (en) * 1999-10-08 2007-08-07 Arius Research Inc. Cancerous disease modifying antibodies
US7189397B2 (en) 1999-10-08 2007-03-13 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US8071072B2 (en) 1999-10-08 2011-12-06 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7419792B2 (en) * 1999-10-08 2008-09-02 Arius Research Inc. Laminin Receptor 1 Precursor Protein (37LRP) epitope delineated by an Hepatocellular carcinoma specific antibody
US7431923B2 (en) * 2005-01-03 2008-10-07 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
US7442777B2 (en) 2000-11-29 2008-10-28 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
AU2003267124A1 (en) 2002-09-09 2004-03-29 Dana-Farber Cancer Institute, Inc. Bh3 peptides and method of use thereof
US7361342B2 (en) * 2003-01-21 2008-04-22 Arius Research Inc. Cancerous disease modifying antibodies
US7195764B2 (en) * 2003-04-14 2007-03-27 Arius Research Inc. Cancerous disease modifying antibodies
EP2008106A2 (en) 2006-03-31 2008-12-31 Dana-Farber Cancer Institute Methods of determining cellular chemosensitivity
US20080089891A1 (en) * 2006-07-26 2008-04-17 Arius Research, Inc. Cancerous disease modifying antibodies
EP2178918A1 (en) * 2007-07-16 2010-04-28 F.Hoffmann-La Roche Ag An anti-cancer cytotoxic monoclonal antibody
US20090022661A1 (en) * 2007-07-16 2009-01-22 Young David S F Cancerous disease modifying antibodies
BRPI0813520A2 (pt) * 2007-07-16 2014-12-23 Hoffmann La Roche Anticorpo monoclonal citotóxico anticâncer
US20090068100A1 (en) * 2007-08-27 2009-03-12 Young David S F Cancerous disease modifying antibodies
US20090068099A1 (en) * 2007-09-10 2009-03-12 Young David S F Cancerous disease modifying antibodies
US20090104115A1 (en) * 2007-10-03 2009-04-23 Young David S F Cancerous disease modifying antibodies
US20090191120A1 (en) * 2008-01-28 2009-07-30 Young David S F Cancerous disease modifying antibodies
US20090191197A1 (en) * 2008-01-28 2009-07-30 Young David S F Cancerous disease modifying antibodies
US20090191119A1 (en) * 2008-01-28 2009-07-30 Young David S F Cancerous disease modifying antibodies
US20090285751A1 (en) * 2008-04-10 2009-11-19 Young David S F Cancerous disease modifying antibodies
WO2009140754A1 (en) * 2008-05-19 2009-11-26 F. Hoffmann-La Roche Ag An anti-cancer cytotoxic monoclonal antibody
US20090304579A1 (en) * 2008-05-19 2009-12-10 Young David S F Cancerous Disease Modifying Antibodies
CA2885230C (en) 2012-09-19 2021-08-03 Anthony Letai Dynamic bh3 profiling
EP3047276B1 (en) 2013-09-19 2023-06-14 Dana-Farber Cancer Institute, Inc. Methods of bh3 profiling
AU2016253957C1 (en) 2015-04-27 2021-04-01 Dana-Farber Cancer Institute, Inc. High throughput BH3 profiling: a rapid and scalable technology to BH3 profile on low numbers of cells

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995020401A1 (en) * 1994-01-31 1995-08-03 Trustees Of Boston University Polyclonal antibody libraries
US6180357B1 (en) * 1999-10-08 2001-01-30 Arius Research, Inc. Individualized patient-specific anti-cancer antibodies

Also Published As

Publication number Publication date
WO2003055515A1 (en) 2003-07-10
AU2002226211A1 (en) 2003-07-15
EP1455819A1 (en) 2004-09-15
JP2005518393A (ja) 2005-06-23

Similar Documents

Publication Publication Date Title
US7420039B2 (en) Individualized anti-cancer antibodies
US7247476B2 (en) Individualized anti-cancer antibodies
CA2471206A1 (en) Individualized anti-cancer antibodies
JP2022088649A (ja) Ｍｕｃ１６に対する抗体およびその使用方法
AU2008235566B2 (en) Anti-EpCAM antibody and uses thereof
JP2007523834A (ja) 癌疾患修飾抗体
US7256271B2 (en) Cancerous disease modifying antibodies
AU2005217007A1 (en) Cancerous disease modifying antibodies
WO2003086456A2 (en) Anti-ck18 monoclonal antibody and therapeutic and diagnostic uses thereof in cancer
EP1360208B1 (en) Method for the production of cytotoxic anti-cancer antibodies
AU2004205435A1 (en) Cancerous disease modifying antibodies
CA2521375A1 (en) Cancerous disease modifying antibodies
WO2005111198A1 (en) Cancerous disease modifying antibodies
US20050027106A1 (en) Cancerous disease modifying antibodies
EP1757305A2 (en) Individualized anti-cancer antibodies

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead